Overview

Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment

Status:
Withdrawn

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

Summary

To evaluate the effects of multiple dose regimens of CHF 5074 administered once per day up to 2 years on potential biomarkers of neurodegeneration in subjects with mild cognitive impairment.

Phase:

Phase 2

Details

Lead Sponsor:

CERESPIR

Treatments:

Flurbiprofen